|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4920016A
(en)
|
1986-12-24 |
1990-04-24 |
Linear Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
US5837258A
(en)
|
1991-08-30 |
1998-11-17 |
University Of South Florida |
Induction of tissue, bone or cartilage formation using connective tissue growth factor
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
ATE356824T1
(de)
|
1999-05-04 |
2007-04-15 |
Santaris Pharma As |
L-ribo-lna analoge
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
CN100523215C
(zh)
|
2000-12-01 |
2009-08-05 |
马普科技促进协会 |
介导rna干涉的小rna分子
|
|
US20080188430A1
(en)
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
|
US20050282188A1
(en)
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
|
US7060809B2
(en)
|
2001-09-04 |
2006-06-13 |
Exiqon A/S |
LNA compositions and uses thereof
|
|
US20050119202A1
(en)
|
2001-10-26 |
2005-06-02 |
Roland Kreutzer |
Medicament to treat a fibrotic disease
|
|
US20040138163A1
(en)
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
KR100464261B1
(ko)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
KR20030084444A
(ko)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
EP1857547B2
(en)
|
2002-08-05 |
2020-12-02 |
Silence Therapeutics GmbH |
Further novel forms of interfering RNA molecules
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
CA2518475C
(en)
|
2003-03-07 |
2014-12-23 |
Alnylam Pharmaceuticals, Inc. |
Irna agents comprising asymmetrical modifications
|
|
US20070167384A1
(en)
|
2003-04-02 |
2007-07-19 |
Dharmacon, Inc. |
Modified polynucleotides for use in rna interference
|
|
US20040198640A1
(en)
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
US20050136437A1
(en)
|
2003-08-25 |
2005-06-23 |
Nastech Pharmaceutical Company Inc. |
Nanoparticles for delivery of nucleic acids and stable double-stranded RNA
|
|
WO2005062937A2
(en)
|
2003-12-22 |
2005-07-14 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
|
|
US20060134787A1
(en)
|
2004-12-22 |
2006-06-22 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
|
|
US20060069050A1
(en)
|
2004-02-17 |
2006-03-30 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
ATE508190T1
(de)
|
2004-03-05 |
2011-05-15 |
Benitec Inc |
Mehrfachpromotor-expressionskassetten zurgleichzeitigen zuführung von rnai-agentien
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
WO2006031901A2
(en)
|
2004-09-10 |
2006-03-23 |
Somagenics, Inc. |
SMALL INTERFERING RNAs THAT EFFICIENTLY INHIBIT VIRAL GENE EXPRESSION AND METHODS OF USE THEREOF
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
TWI386225B
(zh)
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
CA2603842A1
(en)
|
2005-04-08 |
2006-10-19 |
Nastech Pharmaceutical Company Inc. |
Rnai therapeutic for respiratory virus infection
|
|
US8067572B2
(en)
|
2005-05-25 |
2011-11-29 |
The University Of York |
Hybrid interfering RNA
|
|
EP1896069B1
(en)
|
2005-06-24 |
2013-03-13 |
Intervet International BV |
Inactivated chimeric vaccines and related methods of use
|
|
FR2890859B1
(fr)
|
2005-09-21 |
2012-12-21 |
Oreal |
Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
AU2007212700A1
(en)
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
RNA interference agents for therapeutic use
|
|
EP2526968A3
(en)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo receptor antagonists
|
|
US20070218495A1
(en)
|
2006-03-16 |
2007-09-20 |
Dharmacon, Inc. |
Methods, libraries and computer program products for gene silencing with reduced off-target effects
|
|
US7700541B2
(en)
|
2006-04-06 |
2010-04-20 |
Nitto Denko Corporation |
Biodegradable cationic polymers
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
JP2010519907A
(ja)
|
2007-03-02 |
2010-06-10 |
エムディーアールエヌエー，インコーポレイテッド |
Ｖｅｇｆファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
|
|
US20100105134A1
(en)
|
2007-03-02 |
2010-04-29 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
DK2164967T3
(en)
|
2007-05-31 |
2015-10-19 |
Univ Iowa Res Found |
Reduction of off-target rna interferenstoksicitet
|
|
US20090004668A1
(en)
|
2007-06-22 |
2009-01-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pre-miRNA loop-modulated target regulation
|
|
JP2010533170A
(ja)
|
2007-07-12 |
2010-10-21 |
プロセンサ テクノロジーズ ビー．ブイ． |
化合物を種々の選択された臓器、組織又は腫瘍細胞に標的化するための分子
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
EP3121281B1
(en)
|
2007-08-27 |
2021-03-31 |
1Globe Health Institute LLC |
Compositions of asymmetric interfering rna and uses thereof
|
|
JP5723154B2
(ja)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
|
|
CA2701845A1
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
|
US20090131358A1
(en)
|
2007-11-15 |
2009-05-21 |
Alcon Research, Ltd. |
LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
|
|
US8614311B2
(en)
|
2007-12-12 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
RTP801L siRNA compounds and methods of use thereof
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
AU2009215795A1
(en)
|
2008-02-21 |
2009-08-27 |
University Of Kentucky Research Foundation |
Ultra-small RNAs as toll-like receptor-3 antagonists
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
CA2731779A1
(en)
|
2008-07-24 |
2010-01-28 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
US8580562B2
(en)
|
2008-09-08 |
2013-11-12 |
Fukuoka University |
Inhibitory RNA for modulating the molecular function of ZFAT gene
|
|
EP2342340A1
(en)
|
2008-09-22 |
2011-07-13 |
Rxi Pharmaceuticals Corporation |
Rna interference in skin indications
|
|
US20100227920A1
(en)
|
2008-09-29 |
2010-09-09 |
The Regents Of The University Of California |
Aldehyde dehydrogenase inhibitors as novel depigmenting agents
|
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
WO2010094491A1
(en)
|
2009-02-18 |
2010-08-26 |
Silence Therapeutics Ag |
Means for inhibiting the expression of ang2
|
|
JP2012520683A
(ja)
*
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
KR101207561B1
(ko)
|
2009-12-15 |
2012-12-04 |
주식회사 코리아나화장품 |
티로시나제의 발현을 저해하는 ｓｉＲＮＡ 올리고뉴클레오타이드 및 이를 함유하는 화장료 조성물
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
PH12012501596A1
(en)
|
2010-02-24 |
2017-02-03 |
Arrowhead Res Corporation |
Compositions for targeted delivery of sirna
|
|
CA2794189C
(en)
|
2010-03-24 |
2022-01-11 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
|
US9095504B2
(en)
|
2010-03-24 |
2015-08-04 |
Rxi Pharmaceuticals Corporation |
RNA interference in ocular indications
|
|
EP2569445B1
(en)
|
2010-05-12 |
2017-01-04 |
Val-Chum, Limited Partnership |
Screening assays based on abhd6 for selecting insulin secretion promoting agents
|
|
US9290760B2
(en)
|
2010-09-15 |
2016-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
CN103328633B
(zh)
|
2010-10-22 |
2018-07-10 |
成均馆大学校产学协力团 |
诱导rna干扰的核酸分子及其用途
|
|
CA2818024C
(en)
|
2010-12-06 |
2019-09-24 |
Quark Pharmaceuticals, Inc. |
Double stranded oligonucleotide compounds comprising positional modifications
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
RU2582235C2
(ru)
|
2010-12-29 |
2016-04-20 |
Ф.Хоффманн-Ля Рош Аг |
Низкомолекулярные конъюгаты для внутриклеточной доставки нуклеиновых кислот
|
|
CN102719432B
(zh)
|
2011-03-29 |
2013-10-23 |
南京大学 |
特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
|
|
KR101590586B1
(ko)
|
2011-05-30 |
2016-02-01 |
성균관대학교산학협력단 |
표적 유전자 발현 억제 및 면역 반응을 동시에 유발하는 이중가닥의 긴 간섭 ｒｎａ
|
|
WO2013017647A1
(en)
|
2011-08-02 |
2013-02-07 |
Materialise Nv |
Additive manufacturing of openings with reduced dimensions
|
|
JP5696991B2
(ja)
*
|
2011-10-28 |
2015-04-08 |
国立大学法人三重大学 |
ヒトＴＧＦβ１を発現するトランスジェニックマウス
|
|
CA2862628C
(en)
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CN108148838B
(zh)
*
|
2012-05-22 |
2026-07-31 |
奥利克斯医药有限公司 |
具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
|
|
WO2014043291A1
(en)
|
2012-09-12 |
2014-03-20 |
Quark Pharmaceuticals, Inc. |
Double-stranded nucleic acid compounds
|
|
RU2656154C2
(ru)
|
2013-07-05 |
2018-05-31 |
Байонир Корпорейшн |
СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ
|
|
EP3027223A1
(en)
|
2013-07-31 |
2016-06-08 |
QBI Enterprises Ltd. |
Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
|
|
US9790506B2
(en)
|
2013-10-02 |
2017-10-17 |
The Regents Of The University Of California |
Diagnostic and screening methods for atopic dermatitis
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
KR102279110B1
(ko)
|
2014-04-30 |
2021-07-20 |
올릭스 주식회사 |
LasiRNA를 유효성분으로 포함하는 피부 미백용 조성물
|
|
US20170226507A1
(en)
|
2014-05-05 |
2017-08-10 |
The Brigham And Women's Hospital, Inc. |
Coordinate control of pathogenic signaling by the mir-130/301 family in pulmonary hypertension and fibroproliferative diseases
|
|
EP3929293A3
(en)
|
2015-04-03 |
2022-03-16 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
CN108138181B
(zh)
|
2015-07-27 |
2022-05-24 |
奥利克斯医药有限公司 |
抑制黑色素生成的rna复合物
|
|
JP7027311B2
(ja)
|
2015-11-16 |
2022-03-01 |
オリックス ファーマシューティカルズ，インコーポレーテッド |
ＭｙＤ８８又はＴＬＲ３を標的とするＲＮＡ複合体を使用した加齢黄斑変性の治療
|
|
WO2017134525A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
TREATMENT OF ATOPIC DERMATITIS AND ASTHMA USING RNA COMPLEXES THAT TARGET lL4Rα, TRPA1, OR F2RL1
|
|
KR102825945B1
(ko)
|
2016-02-02 |
2025-06-30 |
올릭스 주식회사 |
Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료
|
|
JP7049262B2
(ja)
|
2016-04-11 |
2022-04-06 |
オリックス ファーマシューティカルズ，インコーポレーテッド |
結合組織成長因子を標的とするｒｎａ複合体を用いた特発性肺胞線維症の治療
|
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
|
WO2018146557A2
(en)
|
2017-02-10 |
2018-08-16 |
Dong Ki Lee |
Long double-stranded rna for rna interference
|